Mirum Pharmaceuticals, Inc. (MIRM)
Healthcare • Biotechnology
StockNasdaqGMUnited StatesUS6047491013
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Mirum Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 10:46. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | -0.56 | — | — | Upcoming |
| 03 Nov 2026 16:00 | -0.41 | -0.42 | -0.3% | In line |
| 05 Aug 2026 16:00 | -0.75 | -0.80 | -7.4% | Miss |
| 06 May 2026 16:00 | -0.35 | -1.08 | -205.6% | Miss |
| 25 Feb 2026 16:00 | 0.06 | -0.12 | -308.7% | Miss |
| 04 Nov 2025 16:00 | -0.16 | 0.05 | +131.5% | Beat |
| 06 Aug 2025 16:00 | -0.33 | -0.12 | +64.1% | Beat |
| 07 May 2025 16:00 | -0.27 | -0.30 | -9.7% | Miss |
| 26 Feb 2025 16:00 | -0.25 | -0.49 | -98.7% | Miss |
| 12 Nov 2024 08:00 | -0.45 | -0.30 | +33.0% | Beat |
| 07 Aug 2024 16:00 | -0.46 | -0.52 | -12.3% | Miss |
| 08 May 2024 16:00 | -0.30 | -0.54 | -77.3% | Miss |
| 28 Feb 2024 16:00 | -0.22 | -0.63 | -180.1% | Miss |
| 02 Nov 2023 16:00 | -0.81 | -0.57 | +29.6% | Beat |
| 03 Aug 2023 16:00 | -0.79 | -0.65 | +16.7% | Beat |
| 04 May 2023 16:00 | -0.97 | -0.80 | +17.7% | Beat |
| 08 Mar 2023 16:00 | -0.92 | -0.99 | -7.3% | Miss |
| 09 Nov 2022 07:00 | -1.08 | -1.02 | +6.0% | Beat |
| 04 Aug 2022 16:00 | -1.06 | -0.84 | +20.8% | Beat |
| 05 May 2022 16:00 | -1.38 | -1.17 | +15.2% | Beat |
| 09 Mar 2022 16:00 | 1.84 | -1.61 | -187.9% | Miss |
| 15 Nov 2021 16:00 | -1.50 | -1.60 | -6.7% | Miss |
| 05 Aug 2021 16:00 | -1.08 | -1.45 | -34.6% | Miss |
| 06 May 2021 16:00 | -0.98 | -1.68 | -70.6% | Miss |
| 09 Mar 2021 16:00 | -0.98 | -1.43 | -45.5% | Miss |
| 12 Nov 2020 06:00 | -0.98 | -0.86 | +12.5% | Beat |
| 06 Aug 2020 16:00 | -0.87 | -0.93 | -6.5% | Miss |
| 07 May 2020 16:00 | -0.84 | -0.86 | -2.8% | Miss |
| 12 Mar 2020 16:00 | -0.85 | -0.79 | +6.7% | Beat |
| 06 Nov 2019 16:00 | -0.63 | -0.84 | -34.2% | Miss |
| 28 Aug 2019 16:00 | -0.59 | -0.59 | +0.5% | In line |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 521.3M | +54.7% | -23.4M | -4.5% | -0.47 | +74.6% | 54.9M |
| 2024 | 336.9M | +80.8% | -87.9M | -26.1% | -1.85 | +53.0% | -10.7M |
| 2023 | 186.4M | +141.8% | -163.4M | -87.7% | -3.94 | +2.0% | -91.1M |
| 2022 | 77.1M | — | -135.7M | -176.0% | -4.02 | — | -120.4M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 12 Nov 2026 In progress | 95.10 | 95.39 | 91.46 | 93.33 | -0.42% | 2,257,700 | |
| 02 Nov 2026 – 06 Nov 2026 | 85.55 | 98.97 | 83.13 | 93.72 | +10.26% | 3,905,800 | |
| 26 Oct 2026 – 30 Oct 2026 | 81.76 | 88.51 | 81.16 | 85.00 | +5.73% | 2,793,100 | |
| 19 Oct 2026 – 23 Oct 2026 | 80.90 | 85.84 | 80.24 | 80.39 | +0.31% | 2,907,200 | |
| 12 Oct 2026 – 16 Oct 2026 | 87.22 | 88.31 | 78.35 | 80.14 | -6.82% | 4,017,400 | |
| 05 Oct 2026 – 09 Oct 2026 | 83.30 | 87.79 | 77.78 | 86.01 | +3.71% | 4,951,800 | |
| 28 Sep 2026 – 02 Oct 2026 | 90.00 | 91.25 | 81.41 | 82.93 | -7.55% | 4,580,600 | |
| 21 Sep 2026 – 25 Sep 2026 | 93.07 | 94.57 | 87.64 | 89.70 | -2.32% | 3,644,400 | |
| 14 Sep 2026 – 18 Sep 2026 | 98.37 | 100.50 | 91.73 | 91.83 | -6.51% | 5,163,900 | |
| 08 Sep 2026 – 11 Sep 2026 | 98.49 | 103.28 | 97.01 | 98.22 | -2.66% | 2,188,300 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV (opens in a new tab) Zacks · 11 Nov 2026 16:17
- Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194 (opens in a new tab) Benzinga · 11 Nov 2026 14:21
- Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD (opens in a new tab) 10 Nov 2026 12:30
- No Cost Exome Testing Could Be A Game Changer For GeneDx (WGS) (opens in a new tab) Simply Wall St. · 07 Nov 2026 10:16
- GeneDx and Mirum to provide genetic tests for cholestasis, cataracts or PBD-ZSD (opens in a new tab) Medical Device Network · 06 Nov 2026 11:03
- Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140 (opens in a new tab) Benzinga · 05 Nov 2026 17:23
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing (opens in a new tab) 05 Nov 2026 13:30
- Why Mirum Pharmaceuticals (MIRM) Is Up 11.4% And What's Next After Earnings Beat (opens in a new tab) Simply Wall St. · 05 Nov 2026 04:42
- Mirum (MIRM) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 04 Nov 2026 15:29
- Mirum Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 04 Nov 2026 13:30
- CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target (opens in a new tab) Benzinga · 04 Nov 2026 13:05
- Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167 (opens in a new tab) Benzinga · 04 Nov 2026 09:47
- HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202 (opens in a new tab) Benzinga · 04 Nov 2026 08:50
- Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160 (opens in a new tab) Benzinga · 04 Nov 2026 08:12
- Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance, $500 ... (opens in a new tab) GuruFocus.com · 04 Nov 2026 07:09
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 94.61 USD
- Market cap
- 6.1B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow MIRM and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.